Patents Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
  • Synthesis of benzothiazepines
    Patent number: 9834529
    Abstract: Methods for preparing the following compound are disclosed.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: December 5, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Jiasheng Guo, Bing Liu, Mark B. Mitchell, Michael T. Martin, Xiaoming Zhou
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20170334891
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 23, 2017
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Steven David KNIGHT, Kenneth Allen NEWLANDER, Xinrong TIAN
  • Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2-methylphenyl)urea
    Patent number: 9809540
    Abstract: A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N?-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: November 7, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Francis Dominic Sanderson, Sarah Mary Vallance
  • Long Acting Pharmaceutical Compositions For Hepatitis C
    Publication number: 20170312297
    Abstract: The present Invention relates to long acting pharmaceutical compositions useful in the treatment or prevention or cure of viral infections, such as HCV infections, and diseases associated with such infections.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 2, 2017
    Applicant: Glaxosmithkline Intellectual Property (NO. 2) Limited
    Inventors: Zhi HONG, Martin R. LEIVERS
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 9795597
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: October 24, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Neil W. Johnson, Jiri Kasparec
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
    Patent number: 9775881
    Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 3, 2017
    Assignees: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
  • Fatty acid synthase inhibitors
    Patent number: 9725437
    Abstract: This invention relates to triazolones and triazolones for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: August 8, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventor: Cynthia Ann Parrish
  • Losmapimod for use in treating glomerular disease
    Patent number: 9707219
    Abstract: The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 18, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dennis Sprecher, Robert Nicholas Willette
  • Furopyridines as bromodomain inhibitors
    Patent number: 9670221
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 6, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Paul Bamborough, Michael David Barker, Rino Antonio Bit, John Alexander Brown, Matthew Campbell, Neil Stuart Garton, Matthew J. Lindon, Tracy Jane Shipley, Natalie Hope Theodoulou, Christopher Roland Wellaway, Susan Marie Westaway
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 9637456
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES
    Publication number: 20170100385
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.
    Type: Application
    Filed: May 8, 2015
    Publication date: April 13, 2017
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventor: Michael WASHBURN
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9556157
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 31, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • Compounds as diacylglycerol acyltransferase inhibitors
    Patent number: 9540400
    Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 10, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Donghui Qin, Mui Cheung, Hemant Joshi, Raghuram Tangirala, Sridhar Reddy Bethi
  • Chemical compounds
    Patent number: 9533948
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 3, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • TRPV4 antagonists
    Patent number: 9487507
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 8, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • Method of treatment
    Patent number: 9446041
    Abstract: The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: September 20, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Anna K. Bassil, Soren Beinke, Rabinder Kumar Prinjha
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 9346840
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: May 24, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian, William Henry Miller, Dominic Suarez
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160102083
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 14, 2016
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN